**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 60043

**Manuscript Type:** OPINION REVIEW

**Necessary problems in re-emergence of COVID-19**

Chen S *et al*. Necessary problems of COVID-19 controlling

Si Chen, Lin-Zhu Ren, Hong-Sheng Ouyang, Shen Liu, Li-Ying Zhang

**Si Chen, Lin-Zhu Ren, Hong-Sheng Ouyang, Li-Ying Zhang,** College of Animal Sciences, Jilin University, Changchun 130062, Jilin Province, China

**Shen Liu,** Department of Pharmacy, Jilin Cancer Hospital, Changchun 130000, Jilin Province, China

**Author contributions:** Ren LZ and Liu S conceived the idea for the manuscript; Chen S and Zhang LY wrote the manuscript; Zhang LY and Ouyang HS reviewed the literature.

**Corresponding author: Li-Ying Zhang, PhD, Professor,** College of Animal Sciences, Jilin University, No. 5333 Xi'an Road, Changchun 130062, Jilin Province, China. zhangliy@jlu.edu.cn

**Received:** October 14, 2020

**Revised:** November 5, 2020

**Accepted:** November 21, 2020

**Published online:** January 6, 2021

**Abstract**

The ongoing pandemic of coronavirus disease 2019 poses a great threat to human beings. Although numerous patients have recovered, re-positive cases have been reported in several countries. Till now, we still know very little about the disease and its pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therefore, more attention should be paid to the following aspects, such as post-discharge surveillance, asymptomatic infection, re-evaluation of influenza-like symptoms, and dynamic monitoring of genomic mutation of SARS-CoV-2.

**Key Words:** COVID-19; SARS-CoV-2; Re-positive; Follow-up; Asymptomatic infection

Chen S, Ren LZ, Ouyang HS, Liu S, Zhang LY. Necessary problems in re-emergence of COVID-19. *World J Clin Cases* 2020; 9(1): 1-7 URL: https://www.wjgnet.com/2307-8960/full/v9/i1/1.htm DOI: https://dx.doi.org/10.12998/wjcc.v9.i1.1

**Core Tip:** To date, the re-emergence of coronavirus disease 2019 has been reported in several countries or cities. Therefore, more attention should be paid to the following aspects, such as post-discharge surveillance, asymptomatic infection, re-evaluation of influenza-like symptoms, and dynamic monitoring of genomic mutation of severe acute respiratory syndrome coronavirus 2.

**INTRODUCTION**

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in more than 46840783 confirmed cases and 1204028 deaths in more than 210 countries, areas, or territories by November 3,2020 (<https://www.who.int/>). Cheerfully, numerous patients have recovered and been discharged from the hospital after careful treatment by medical staff with candidate chemical medicine and traditional Chinese medicines[1]. However, several studies showed that positive results of SARS-CoV-2 were detected in many recovered patients[2-6]. The total re-positive rate is 7.7%-19.8% or even higher[2,3]. Furthermore, 52% and 30% of re-positive patients had IgG and IgM antibodies against SARS-CoV-2, respectively, while 35% of them exhibit one or more COVID-19-related symptoms[6]. To date, the re-emergence of the disease has also been reported in several countries or cities. Therefore, more attention should be paid to the following aspects.

**POST-DISCHARGE SURVEILLANCE IS NECESSARY FOR RECOVERED PATIENTS**

The occurrence of reinfection or re-positivity in the recovered patient may be caused by the following reasons. First, the detection method used to evaluate the disease has a poor sensitivity or low sensitivity to clinical samples, resulting in false-negative error. Currently, although many detection methods were reported and used for diagnosis of the SARS-CoV-2 infection, different methods have different sensitivities and specificities, with different degrees of error rates[7]. A case recently reported in China showed that the results of the first seven tests were negative, but the eighth test confirmed it as a COVID-19 case. These results suggest that more sensitive and specific diagnostic methods are still needed to be developed for COVID-19 detection.

Second, the sampling method, samples, and sampling time may affect the diagnosis. As reported, SARS-CoV-2 was found in many organs, such as the lungs, lymph nodes, spleen, liver, heart, kidneys, semen, brain, and blood, suggesting that the virus can infect and replicate in almost all human organs. However, the amount of virus in different tissues is different. A case report showed that the rectal swabs of six discharged patients were positive and the throat swabs of one discharged patient were positive, but the throat swabs of all seven discharged patients were negative[8]. They also found that the time from discharge to positive RT-PCR after recovery is 7-11 d[8]. Moreover, it was reported that SARS-CoV-2 is more mysterious and infectious than other viruses. Thus, the virus may escape from the host's immune system and hide in somewhere of the body that cannot be detected by currently used diagnostic methods. Besides, prolonged but intermittent viral shedding from the recovered patient may also affect the levels of virus in the samples[3]. Therefore, samples of different tissues, especially samples from the lower respiratory tract, should be selected simultaneously for diagnosis.

The third possible cause may be the discontinuation of antiviral drugs as reported by Wu and colleagues[9]. To date, no effective antiviral medicines have been obtained worldwide. Although several drugs, including chemical drugs, traditional Chinese medicine, and other drugs, have antiviral effects[1], these drugs cannot eliminate the virus in the body, but can only inhibit the replication of the virus to a certain extent, leading to asymptomatic infection in re-positive patients. Thus, the surviving virus can still replicate in large quantities after drug withdrawal, resulting in positive results of nucleic acid tests or even worse. In addition, Wong *et al*[3] found that the re-positive risk of women is about one third higher than that of men, the re-positive risk of symptomatic patients is at least twice that of asymptomatic patients, and the re-positive risk of patients taking lopinavir/ritonavir is more than 50% higher than that of patients not taking lopinavir[3]. Moreover, recent results showed that lopinavir/ritonavir is not effective in the treatment of COVID-19[10,11]. These results suggest that the reasons for the recovered patients testing positive again may be varied and the probability of re-positive rate may be relatively high.

Importantly, as reported previously, lipid metabolism was changed[12] and peripheral memory B cell response was undetectable[13] in the recovered SARS-CoV patient in long-term follow-up studies, suggesting that SARS-CoV may cause some clinical sequela in the recovered patients. Since SARS-CoV-2 and SARS-CoV belong to the same family *(Coronavirus* family), and SARS-CoV-2 is more infectious than the latter, whether the SARS-CoV-2 will bring some adverse prognosis to the recovered patients still needs further long-term follow-up study.

Therefore, it is necessary to conduct a long-term follow-up study for recovered patients. Notably, it is necessary to re-evaluate the current standards for patients to be discharged from the hospital or to stop quarantine and continue treatment.

**ASYMPTOMATIC INFECTION PLAYS A CRUCIAL ROLE IN RE-EMERGENCE OF THE DISEASE**

Asymptomatic infection, also known as inapparent or subclinical infection, is widely found in viral infectious diseases and protozoa-related diseases, such as Ebola virus, human immunodeficiency virus, and *Babesia*. It refers to an infection that has no clinical symptoms but is positive by nucleic acid detection. However, when the conditions are suitable, the virus may replicate in large numbers and eventually spread among individuals. As reported by several studies[1,14,15], a high proportion (43%-50%) of asymptomatic infections were found in the respiratory tract and saliva samples of quarantined people, which may pose an increasing threat to human health, with the continuous increase of the traveling population worldwide.

It was reported that a patient with asymptomatic infection of SARS-CoV-2 must have a medical history of contact with the confirmed patient, or he/she has been to the epidemic area where the epidemic is occurring. Therefore, asymptomatic infection of COVID-19 may occur for several possible reasons. First, the incubation period of the SARS-CoV-2 is 1 to 14 d or even as long as 24 d in some cases[16,17]. At the initial stage of infection, the amount of virus is relatively small, and thus no clinical symptoms occur. Second, because the infected person is in good physical condition, the immune system of the infected person effectively inhibits the viral infection process. Third, the virus infection is mild, which is not enough to stimulate an effective immune response in the human body. Moreover, other reasons, such as living environment conditions and basic diseases, will also affect the virus infection and the disease process.

It is worth noting that at present we still know very little about COVID-19 and SARS-CoV-2. However, despite asymptomatic infection, the virus may replicate in the human body and shed from the infected person, thus leading to transmission at the community level[15]. Huang *et al*[18] reported that SARS-CoV-2 can spread asymptomatically and rapidly during the incubation period[18], which was further confirmed by the World Health Organization on July 9, 2020. Chang and colleagues reported that half of the patients with COVID-19 were viral positive even after the resolution of their symptoms up to 8 d[19], which may be one of the reasons why some recovered patients return to positive. These results indicate that the virus is infectious in the asymptomatic stage and in some cases in convalescent patients, which may become a potential source of SARS-CoV-2 infection or the main driving force of the current pandemic.

Therefore, monitoring asymptomatic infection among the population, especially recent travelers, is undoubtedly an urgent task for controlling the COVID-19. Clinically, nucleic acid detection methods are sensitive but prone to false negatives, while antibody detection methods are slightly less sensitive but more accurate. Thus, we suggest combining the two methods to detect asymptomatic infection of COVID-19.

**RE-EVALUATION OF SAMPLES FROM THE PATIENT WITH INFLUENZA-LIKE SYMPTOMS IS BETTER FOR TRACKING THE ORIGIN OF THE VIRUS**

Because the symptoms of COVID-19 are similar to those of influenza and other respiratory infections, COVID-19 patients may likely be treated as ordinary influenza patients, resulting in a missed diagnosis. Kong and colleagues re-analyzed 640 throat swabs collected from patients in Wuhan with influenza-like-illness and found that 9 of the 640 throat swabs were positive for SARS-CoV-2 RNA by quantitative PCR[20]. Lu *et al*[21] estimated that as of May 16, 2020, the actual cases of COVID-19 may be 5 to 10 times more than the reported cases, and the total estimated number of cases in the United States is between 6 million and 12.2 million[21]. Thus, monitoring influenza-like diseases and re-evaluating the samples from patients with influenza-like symptoms may provide a broader understanding of COVID-19, which may be helpful to trace the source and transmission route of SARS-CoV-2.

Moreover, although the symptoms of influenza and COVID-19 are similar, there are several clinical differences between COVID-19 and influenza or other respiratory infections. It was reported that anosmia, dysgeusia, diarrhea, frontal headache, and bilateral cracklings sounds were statistically more common in COVID-19, while sputum production, dyspnea, sore throat, conjunctival hyperhemia, tearing, vomiting, and rhonchi sounds were more frequent with influenza infection[22]. Besides, COVID-19 patients may become critically ill in the second week post-infection (about day 10), while influenza patients get worse at the end of the first week post-infection (about day 7)[22]. Symptom monitoring as well as pathogen identification can provide a more timely choice for first-line screening and public health interventions on the diseases as well as seasonal influenza[23,24]. Therefore, it is an urgent need to develop methods to distinguish COVID-19 cases from other upper respiratory tract and/or influenza-like diseases.

**DYNAMIC MONITORING OF GENOMIC MUTATION OF SARS-COV-2 ISOLATE IS IMPORTANT**

SARS-CoV-2 belongs to the *Coronavirus* family, *Betacoronavirus* genus, and *Sarbecovirus* subgenus, containing a linear single positive-stranded RNA genome of about 30 kb[25]. Recent reports showed that mutations occur in the population due to RNA editing in the transcriptome of SARS-CoV-2 or nucleotide substitutions in the viral genome[26-32]. A synonymous mutation of D614G was located in the B cell epitope of viral S1 domain, by which SARS-CoV-2 can be divided into two subtypes, SARS-CoV-2a and SARS-CoV-2b[33]. Moreover, SARS-CoV-2b strains exhibit severely reduced antigenicity compared with that of SARS-CoV-2a[33]. The D614G mutation in the viral spike protein reduces S1 shedding and increases the infectivity of SARS-CoV-2[25,30]. Pachetti and colleagues found eight mutation hot spots of SARS-CoV-2 at positions 1397, 2891, 14408, 17746, 17857, 18060, 23403, and 28881, including a novel mutation of RNA-dependent RNA polymerase (RdRp) at position 14408[32], which may affect the recognition of antiviral drugs and RdRp, and the binding of RdRp and template RNA. These results indicate that the mutation may substantially affect the viral transmission, pathogenicity, and drug-resistance phenotypes as well as antigenicity and immunogenicity of vaccines.

Furthermore, numerous pieces of evidence show that SARS-CoV-2 infection has occurred in humans for a long time or even years ago. A recent report showed the spike protein receptor binding domain (RBD) may have a high affinity for human cell targets at least since 2013[34]. Besides, the vaccine is the best way to prevent and control virus infection, however, although several candidate vaccines have been applied in clinical trials, the efficacy and safety of these vaccines still need further evaluation. Notably, it was reported that the majority of the analyzed population is seronegative to SARS-CoV-2 infection, as low seroprevalence was observed in COVID-19 hotspots, with 5%-10% in Spain, 10.8% in Swiss, 7.3% in Sweden, and 3.8% in Wuhan, China[35,36], suggesting that the natural herd immunity in the population is not suitable for SARS-CoV-2 infection and effective vaccine against the disease is urgently needed. Therefore, the study of virus mutation can provide a basis for virus traceability, and is also beneficial to the design and development of an efficient and safe vaccine.

**CONCLUSION**

In conclusion, the COVID-19 epidemic has brought great harm to human beings. However, little is known about the disease and SARS-CoV-2 virus. In particular, recent reports show that the epidemic has risen for the second wave in Europe, and re-infection of the virus occurs in some countries[37-39]. SARS-CoV-2 D614G variant exhibits enhanced binding, replication, and transmission activities *in vitro* and *in vivo*[40,41]. Therefore, more stringent strategies are needed to control the spread of the virus, such as post-discharge surveillance of recovered patients, monitoring asymptomatic infections, re-evaluating samples of a patient with influenza-like symptoms, and dynamically monitoring genomic mutation of SARS-CoV-2 isolates.

**REFERENCES**

1 **Wang Y**, Tong J, Qin Y, Xie T, Li J, Li J, Xiang J, Cui Y, Higgs ES, Xiang J, He Y. Characterization of an asymptomatic cohort of SARS-COV-2 infected individuals outside of Wuhan, China. *Clin Infect Dis* 2020; ciaa62 [PMID: 32442265 DOI: 10.1093/cid/ciaa629]

2 **Luo S**, Guo Y, Zhang X, Xu H. A follow-up study of recovered patients with COVID-19 in Wuhan, China. *Int J Infect Dis* 2020; **99**: 408-409 [PMID: 32497798 DOI: 10.1016/j.ijid.2020.05.119]

3 **Wong J**, Koh WC, Momin RN, Alikhan MF, Fadillah N, Naing L. Probable causes and risk factors for positive SARS-CoV-2 test in recovered patients: Evidence from Brunei Darussalam. *J Med Virol* 2020; 10.1002/jmv.26199 [PMID: 32558947 DOI: 10.1002/jmv.26199]

4 **Lan L**, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H. Positive RT-PCR Test Results in Patients Recovered From COVID-19. *JAMA* 2020; **323**: 1502-1503 [PMID: 32105304 DOI: 10.1001/jama.2020.2783]

5 **Zou Y**, Wang BR, Sun L, Xu S, Kong YG, Shen LJ, Liang GT, Chen SM. The issue of recurrently positive patients who recovered from COVID-19 according to the current discharge criteria: investigation of patients from multiple medical institutions in Wuhan, China. *J Infect Dis* 2020; **222(11)**: 1784-1788 [PMID: 32491178 DOI: 10.1093/infdis/jiaa301]

6 **Mei Q,** Li J, Du R, Yuan X, Li M, Li J. Assessment of patients who tested positive for COVID-19 after recovery. *Lancet Infect Dis* 2020; **20:** 1004-1005 [PMID: 32645295 DOI: 10.1016/S1473-3099(20)30433-3]

7 **Li C**, Ren L. Recent progress on the diagnosis of 2019 Novel Coronavirus. *Transbound Emerg Dis* 2020; **67**: 1485-1491 [PMID: 32395897 DOI: 10.1111/tbed.13620]

8 **Zhang B**, Liu S, Dong Y, Zhang L, Zhong Q, Zou Y, Zhang S. Positive rectal swabs in young patients recovered from coronavirus disease 2019 (COVID-19). *J Infect* 2020; **81**: e49-e52 [PMID: 32335176 DOI: 10.1016/j.jinf.2020.04.023]

9 **Wu F**, Zhang W, Zhang L, Wang D, Wan Y. Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again. *Br J Hosp Med (Lond)* 2020; **81**: 1-2 [PMID: 32339007 DOI: 10.12968/hmed.2020.0156]

10 **Cao B,** Wang Y, Wen D, Liu W, Wang JL, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li HD, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* 2020; **382(19):** 1787-1799 [PMID: 32187464 DOI: 10.1056/NEJMoa2001282]

11 **Horby PW,** Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, Palfreeman A, Raw J, Elmahi E, Prudon B, Green C, Carley S, Chadwick D, Davies M, Wise MP, Baillie JK, Chappell LC, Faust SN, Jaki T, Jefferey K, Lim WS, Montgomery A, Rowan K, Juszczak E, Haynes R, Landray MJ. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2020; **396:** 1345–1352 [PMID: 33031764 DOI: 10.1016/S0140-6736(20)32013-4]

12 **Wu Q**, Zhou L, Sun X, Yan Z, Hu C, Wu J, Xu L, Li X, Liu H, Yin P, Li K, Zhao J, Li Y, Wang X, Li Y, Zhang Q, Xu G, Chen H. Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection. *Sci Rep* 2017; **7**: 9110 [PMID: 28831119 DOI: 10.1038/s41598-017-09536-z]

13 **Tang F**, Quan Y, Xin ZT, Wrammert J, Ma MJ, Lv H, Wang TB, Yang H, Richardus JH, Liu W, Cao WC. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. *J Immunol* 2011; **186**: 7264-7268 [PMID: 21576510 DOI: 10.4049/jimmunol.0903490]

14 **Chau NVV**, Thanh Lam V, Thanh Dung N, Yen LM, Minh NNQ, Hung LM, Ngoc NM, Dung NT, Man DNH, Nguyet LA, Nhat LTH, Nhu LNT, Ny NTH, Hong NTT, Kestelyn E, Dung NTP, Xuan TC, Hien TT, Thanh Phong N, Tu TNH, Geskus RB, Thanh TT, Thanh Truong N, Binh NT, Thuong TC, Thwaites G, Tan LV; OUCRU COVID-19 research group. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. *Clin Infect Dis* 2020; ciaa711 [PMID: 32497212 DOI: 10.1093/cid/ciaa711]

15 **Huff HV**, Singh A. Asymptomatic transmission during the COVID-19 pandemic and implications for public health strategies. *Clin Infect Dis* 2020; ciaa654 [PMID: 32463076 DOI: 10.1093/cid/ciaa654]

16 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

17 **Linton NM**, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B, Kinoshita R, Nishiura H. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. *J Clin Med* 2020; **9**: 538 [PMID: 32079150 DOI: 10.3390/jcm9020538]

18 **Huang L**, Zhang X, Zhang X, Wei Z, Zhang L, Xu J, Liang P, Xu Y, Zhang C, Xu A. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. *J Infect* 2020; **80**: e1-e13 [PMID: 32283156 DOI: 10.1016/j.jinf.2020.03.006]

19 **Chang**, Mo G, Yuan X, Tao Y, Peng X, Wang FS, Xie L, Sharma L, Dela Cruz CS, Qin E. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. *Am J Respir Crit Care Med* 2020; **201**: 1150-1152 [PMID: 32200654 DOI: 10.1164/rccm.202003-0524LE]

20 **Kong WH**, Li Y, Peng MW, Kong DG, Yang XB, Wang L, Liu MQ. SARS-CoV-2 detection in patients with influenza-like illness. *Nat Microbiol* 2020; **5**: 675-678 [PMID: 32265517 DOI: 10.1038/s41564-020-0713-1]

21 **Lu FS**, Nguyen AT, Link NB, Lipsitch M, Santillana M. Estimating the Early Outbreak Cumulative Incidence of COVID-19 in the United States: Three Complementary Approaches. *medRxiv* 2020; 20070821 [PMID: 32587997 DOI: 10.1101/2020.04.18.20070821]

22 **Zayet S**, Kadiane-Oussou NJ, Lepiller Q, Zahra H, Royer PY, Toko L, Gendrin V, Klopfenstein T. Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. *Microbes Infect* 2020; **22**: 481-488 [PMID: 32561409 DOI: 10.1016/j.micinf.2020.05.016]

23 **Wen A**, Wang L, He H, Liu S, Fu S, Sohn S, Kugel JA, Kaggal VC, Huang M, Wang Y, Shen F, Fan J, Liu H. An Aberration Detection-Based Approach for Sentinel Syndromic Surveillance of COVID-19 and Other Novel Influenza-Like Illnesses. *MedRxiv [Preprint]* 2020; 2020.06.08.20124990 [PMID: 32577704 DOI: 10.1101/2020.06.08.20124990]

24 **Jiang C**, Yao X, Zhao Y, Wu J, Huang P, Pan C, Liu S, Pan C. Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season. *Microbes Infect* 2020; **22**: 236-244 [PMID: 32405236 DOI: 10.1016/j.micinf.2020.05.005]

25 **Korber B,** Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC, Angyal A, Brown RL, Carrilero L, Green LR, Groves DC, Johnson KJ, Keeley AJ, Lindsey BB, Parsons PJ, Raza M, Rowland-Jones S, Smith N, Tucker RM, Wang D, Wyles MD. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* 2020; **182(4):** 812-827.e19 [PMID: 32697968 DOI: 10.1016/j.cell.2020.06.043]

26 **Demİr AB**, Benvenuto D, AbacioĞlu H, Angeletti S, Ciccozzi M. Identification of the nucleotide substitutions in 62 SARS-CoV-2 sequences from Turkey. *Turk J Biol* 2020; **44**: 178-184 [PMID: 32595354 DOI: 10.3906/biy-2005-69]

27 **Yao H,** Lu X, Chen Q, Xu K, Chen Y, Cheng L, Liu F, Wu Z, Wu H, Jin C, Zheng M, Wu N, Jiang C, Li L. Patient-derived mutations impact pathogenicity of SARS-CoV-2. *medRxiv* 2020 [DOI: 10.1101/2020.04.14.20060160]

28 **Di Giorgio S**, Martignano F, Torcia MG, Mattiuz G, Conticello SG. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. *Sci Adv* 2020; **6**: eabb5813 [PMID: 32596474 DOI: 10.1126/sciadv.abb5813]

29 **Ugurel OM**, Ata O, Turgut-Balik D. An updated analysis of variations in SARS-CoV-2 genome. *Turk J Biol* 2020; **44**: 157-167 [PMID: 32595352 DOI: 10.3906/biy-2005-111]

30 **Zhang L**, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. *bioRxiv* 2020; 2020.06.12.148726 [PMID: 32587973 DOI: 10.1101/2020.06.12.148726]

31 **Simmonds P**. Rampant C→U Hypermutation in the Genomes of SARS-CoV-2 and Other Coronaviruses: Causes and Consequences for Their Short- and Long-Term Evolutionary Trajectories. *mSphere* 2020; **5**: e00408-20 [PMID: 32581081 DOI: 10.1128/mSphere.00408-20]

32 **Pachetti M**, Marini B, Benedetti F, Giudici F, Mauro E, Storici P, Masciovecchio C, Angeletti S, Ciccozzi M, Gallo RC, Zella D, Ippodrino R. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. *J Transl Med* 2020; **18**: 179 [PMID: 32321524 DOI: 10.1186/s12967-020-02344-6]

33 **Kim SJ**, Nguyen VG, Park YH, Park BK, Chung HC. A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity? *Vaccines (Basel)* 2020; **8**: 220 [PMID: 32422894 DOI: 10.3390/vaccines8020220]

34 **Brintnell E,** Gupta M, Anderson DW. Detailed phylogenetic analysis of SARS-CoV-2 reveals latent capacity to bind human ACE2 receptor. *bioRxiv* 2020; 2020.2006.2022.165787 [DOI: 10.1101/2020.06.22.165787]

35 **Pollán M**, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, Sanmartín JL, Fernández-García A, Cruz I, Fernández de Larrea N, Molina M, Rodríguez-Cabrera F, Martín M, Merino-Amador P, León Paniagua J, Muñoz-Montalvo JF, Blanco F, Yotti R; ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet* 2020; **396**: 535-544 [PMID: 32645347 DOI: 10.1016/S0140-6736(20)31483-5]

36 **Eckerle I**, Meyer B. SARS-CoV-2 seroprevalence in COVID-19 hotspots. *Lancet* 2020; **396**: 514-515 [PMID: 32645348 DOI: 10.1016/S0140-6736(20)31482-3]

37 **To KK**, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, Fong CH, Yuan S, Tsoi HW, Ng AC, Lee LL, Wan P, Tso E, To WK, Tsang D, Chan KH, Huang JD, Kok KH, Cheng VC, Yuen KY. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. *Clin Infect Dis* 2020; ciaa1275 [PMID: 32840608 DOI: 10.1093/cid/ciaa1275]

38 **AlFehaidi A**, Ahmad SA, Hamed E. SARS-CoV-2 re-infection: a case report from Qatar. *J Infect* 2020; S0163-4453(20)30677-0 [PMID: 33115660 DOI: 10.1016/j.jinf.2020.10.019]

39 **Bongiovanni M**. COVID-19 re-infection in an healthcare worker. *J Med Virol* 2020; 10.1002/jmv.26565 [PMID: 32990954 DOI: 10.1002/jmv.26565]

40 **Zhou B**, Thao TTN, Hoffmann D, Taddeo A, Ebert N, Labroussaa F, Pohlmann A, King J, Portmann J, Halwe NJ, Ulrich L, Trüeb BS, Kelly JN, Fan X, Hoffmann B, Steiner S, Wang L, Thomann L, Lin X, Stalder H, Pozzi B, de Brot S, Jiang N, Cui D, Hossain J, Wilson M, Keller M, Stark TJ, Barnes JR, Dijkman R, Jores J, Benarafa C, Wentworth DE, Thiel V, Beer M. SARS-CoV-2 spike D614G variant confers enhanced replication and transmissibility. *bioRxiv* 2020; 2020.10.27.357558 [PMID: 33140052 DOI: 10.1101/2020.10.27.357558]

41 **Hou YJ**, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH, Leist SR, Schäfer A, Nakajima N, Takahashi K, Lee RE, Mascenik TM, Edwards CE, Tse LV, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS. SARS-CoV-2 D614G Variant Exhibits Enhanced Replication *ex vivo* and Earlier Transmission *in vivo*. *bioRxiv* 2020; 2020.09.28.317685 [PMID: 33024969 DOI: 10.1101/2020.09.28.317685]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflict of interest involved.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** October 14, 2020

**First decision:** November 3, 2020

**Article in press:** November 21, 2020

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Słomka A, Warabi Y **S-Editor:** Fan JR **L-Editor:** Wang TQ **P-Editor:** Xing YX